Canada markets open in 3 hours 48 minutes

Accolade, Inc. (ACCD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
44.40+0.80 (+1.83%)
At close: 4:00PM EDT
Sign in to post a message.
  • M
    Michael
    $CSLT conversation
    CEO and CFO sold 120,000 shares yesterday. This may continue to weight on the stock price.

    Last insider buying was in March, 2020 at $0.84 per share. Board member and execs have only been selling since March , 2020, but they also get shares as compensation.

    Most stocks in the “digital health” investment area has been declining meaningfully lately, it’s not just CSLT.

    Look at the charts of $TDOC $AMWL $SHCR $ACCD $GOCO since February. They are not pretty.

    Also, small caps in general have been week recently.
  • d
    dannatt
    If you’re looking for a short and sweet guide to the day’s biggest news, I recommend (http://Fairstox.com). They breakdown the most important pre-market news and it only takes a few minutes to read.
  • M
    Michael
    $CSLT conversation
    Based on my research, CSLT continues to struggle to close deals and seems to be losing employer deals to $ACCD and Quantum Health (I.e. same as last several quarters) and I expect a decent number of CSLT cancellations this quarter, albeit, not as bad as 3Q20 (which was really bad when ARR fell $8 million or 6% sequentially).

    As long as CSLT retains Anthem (approx 50% of revenues), downside should be limited to $1.35 per share, as the valuation is compelling. I expect an Anthem decision (retain or lose) in early 2022.

    Interestingly, CSLT comps ($ACCD, $TDOC, $AMWL, $SHCR) are trading on avg 50% below 52-week highs and 15-20% above 52-week lows.

    This metric implies CSLT should be between $1.00 and $1.35, BUT CSLT’s 52-week low was unreasonably low and some of the 52-week highs of the other companies were unreasonably high.

    I think the current price for CSLT around $1.60 to $1.80 is probably appropriate as we wait for 3Q21 results, but the last few intro-quarter swings have been from approx. $1.30 to above $2.50, so this stock can be quite volatile on no news.

    I would be surprised to ever see the stock below $1.00 again, because if CSLT loses Anthem, the company will likely sell itself and I think it’s technology platform is worth $1.50 per share to an acquirer.

    Short interest has been building slightly and I don’t know if that’s technical bets or negative fundamental views on CSLT.
  • Y
    Yahoo Finance Insights
    Accolade is up 6.39% to 47.21
  • Y
    Yahoo Finance Insights
    Accolade is down 6.01% to 45.68
  • T
    Tim S
    Cathy Wood buy today
  • T
    TheBearishBull
    Buy the dip
  • Y
    Yahoo Finance Insights
    Accolade is down 6.68% to 49.73
  • Y
    Yahoo Finance Insights
    Accolade is down 6.90% to 46.72
  • d
    dunkleman
    This is one of the few KW stocks that isn’t moving...
  • Y
    Yahoo Finance Insights
    Accolade is up 6.74% to 48.88
  • R
    RahTheFast
    this company has lot of potential. what if Accolade and MDLive merged. it would be over $100.
  • D
    Deez
    No organic growth here.
    Guiding to $260M in 2022FY revenue. 2 acquisitions posted $70M revenue in 2021 (Plushcare, 2ndMD). Even if these acquisitions stay flat in 2022, that implies organic revenue of $190M in '22 vs. $176M in '21. No growth.
    Stronger growth coming from Grand Rounds / Doctor On Demand (will be public soon), $CSLT, and Quantum (just did PE recap).
  • R
    RahTheFast
    CSLT is bad. no potential. look at Livingo who came way after CSLT. you need innovation in Healthcare IT world, not coping people to get by.
  • C
    Celyn
    how to see any news for this stock?
  • l
    lava
    maybe insiders are sending the sell signal
  • A
    Anonymous
    Why does anything ark fund touches turn to gold, it has with nvta, #1 of 43 stocks they own.
  • Y
    Yahoo Finance Insights
    ACCD is down 9.42% to 38.07
  • J
    Jeff
    There seems to be a lot of risk built into the share price.
  • K
    K
    historically, we are looking at about 20-30% consistent upside from this price.